MA-READSPEAKER
15.3.2022 13:32:07 CET | Business Wire | Press release
ReadSpeaker , the most trusted, independent digital voice partner for global businesses, today announced the industry’s first-ever multi-platform Runtime Text-to-Speech (TTS) Plugin for Unreal and Unity game engines. With the ReadSpeaker TTS plugin, game developers can leverage a single runtime TTS solution across multiple platforms, allowing them to add screen narration, audio description and more to their game. The plugin can also be leveraged to give the power of speech to AI-based non-player characters (NPCs) and prototype character lines during development.
With the explosion in popularity of gaming during the pandemic, improving the experience for both developers and players is a critical need. By leveraging the ReadSpeaker runtime TTS plugin, Unity and Unreal game developers can create and edit speech for audio cues and narration with near zero latency, enabling them to prototype speech without the need for voice actors. This allows developers to experiment with new ideas and concepts so they can deliver the best product possible more quickly.
With the plugin, developers do not need to produce and manage individual audio files and can code speech directly into the game, improving accessibility by leveraging TTS to add user interface narration and audio description. With these capabilities, players can have procedurally generated text read aloud to them with near zero latency, and also have the option to have in-game chat messages narrated to them, a critical component of action-heavy multiplayer games.
“ReadSpeaker’s runtime TTS plugin is a game changer for developers and players alike,” said Conor Bradley, Company Director, Soft Leaf Studios. “For developers, the plugin enables a streamlined workflow, allowing them to test, trigger and retest quickly, without the need to wait for outside feedback. And because the plugin comes with pre-made voice adjusters, coding needs are reduced. For players, the TTS plugin enables them to personalize the game to their needs, improving accessibility for those who need it.”
“Digital environments and the development of the Metaverse are becoming ever more limitless, putting pressure on developers to deliver higher-quality experiences for players—especially when it comes to voice,” says Matt Muldoon, President North America, ReadSpeaker. “By powering these digital environments with AI and TTS and automating prospective expansions, developers are able to create unique experiences each time for each player. Our Runtime TTS plugin for Unity and Unreal game engines gives developers and players the ability to fully immerse themselves in these digital worlds as they continue to expand and become more powerful.”
For more on ReadSpeaker’s Runtime TTS Plugin, visit https://www.readspeaker.ai/unity-unreal-game-engine-plugin-free-trial/ .
About ReadSpeaker:
ReadSpeaker is the most trusted, independent digital voice partner for global brands. With more than 20 years of industry experience, ReadSpeaker offers brands sophisticated text-to-speech solutions and expert hands-on assistance to create the most engaging bespoke voice interfaces. ReadSpeaker offers both SaaS and licensed solutions to support varying channels and devices, and consistently maintains brand trust through its commitment to data privacy. To date, the company – which provides more than 35 languages and 110 voices – has created more than 10,000 digital voice interfaces for brands around the world. For more information, visit https://www.readspeaker.ai/
and follow the company on Twitter
and LinkedIn
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220222006347/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
